title: In vivo treatment with a monoclonal antibody to T helper cells in experimental autoimmune glomerulonephritis in the BN rat.
abstract: Experimental autoimmune glomerulonephritis (EAG) was induced in brown Norway (BN) rats by a single i.m. injection of homologous glomerular basement membrane (GBM) in Freund's complete adjuvant. This model of anti-GBM disease is characterized by the development, over several weeks, of circulating and deposited anti-GBM antibodies, accompanied by albuminuria. We examined the effects of treatment with MoAb W3/25 (anti-CD4) at different doses, starting at the time of immunization and continued for the duration of the study or for a limited period only. Continued treatment with W3/25, at a dose of 5 or 10 mg/kg intraperitoneally three times per week for 4 weeks, produced a marked reduction in circulating anti-GBM antibodies, absence of detectable deposited antibody and virtual absence of albuminuria. When W3/25 treatment, at 5 or 10 mg/kg, was stopped after 2 weeks, there was still a significant reduction in anti-GBM antibodies and albuminuria at 4 weeks. A similar effect on the disease was achieved when W3/25 was administered only three times during the first week at a dose of 30 mg/kg. Animals injected with W3/25 at a dose of 10 mg/kg through the course of disease showed < 10% W3/25+ cells by FACS analysis of splenic lymphocytes at week 4, while controls and animals treated for shorter periods showed > 30% W3/25+ cells. These results demonstrate that W3/25 can prevent the development of EAG, and that this effect is not dependent on persistent depletion of T cells. Further work is necessary to determine whether anti-T cell therapy is effective in established EAG, and may be worth investigating in human anti-GBM disease.
authors.affiliation: Department of Medicine, Royal Postgraduate Medical School, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Reynolds
authors.forename: C D
authors.initials: CD
authors.lastname: Pusey
mesh_terms: D000419:Albuminuria / Q000628:therapy; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000473:pathology / Q000628:therapy*; D015704:CD4 Antigens / Q000502:physiology*; D005455:Fluorescent Antibody Technique; D005921:Glomerulonephritis / Q000473:pathology / Q000628:therapy*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D006377:T-Lymphocytes, Helper-Inducer / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens